Auro Laboratories Limited Stock Price Today (NSE: AUROLAB)
Fundamental Score
Auro Laboratories Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Auro Laboratories Limited share price today is ₹251.15, up +0.42% on NSE/BSE as of 22 September 2026. Auro Laboratories Limited (AUROLAB) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹156.53 (Cr). The 52-week high for AUROLAB share price is ₹317.00 and the 52-week low is ₹159.00. At a P/E ratio of 33.41x, AUROLAB is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 7.90% and a debt-to-equity ratio of 1.37.
Auro Laboratories Limited Share Price Chart — NSE/BSE Historical Performance
Auro Laboratories Limited share price chart: 9.39% return over the past month. 52-week high ₹317.00, 52-week low ₹159.00.
Auro Laboratories Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹250.00 | ₹258.70 | ₹245.55 | ₹250.10 | 2.52K (Cr) | |
| ₹249.00 | ₹259.00 | ₹243.90 | ₹249.90 | 4.95K (Cr) | |
| ₹250.00 | ₹254.50 | ₹237.05 | ₹244.40 | 1.44K (Cr) | |
| ₹249.90 | ₹253.80 | ₹239.00 | ₹247.90 | 1.47K (Cr) | |
| ₹253.80 | ₹261.90 | ₹236.20 | ₹243.20 | 2.99K (Cr) | |
| ₹254.00 | ₹261.75 | ₹247.00 | ₹253.80 | 38.21K (Cr) | |
| ₹254.00 | ₹260.70 | ₹246.05 | ₹256.95 | 3.02K (Cr) | |
| ₹256.75 | ₹260.00 | ₹252.00 | ₹256.75 | 2.17K (Cr) | |
| ₹261.00 | ₹262.00 | ₹256.15 | ₹256.75 | 6.82K (Cr) | |
| ₹255.00 | ₹262.50 | ₹249.75 | ₹257.65 | 10.63K (Cr) |
Auro Laboratories Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹236.00 | ₹267.80 | ₹226.00 | ₹250.10 | +5.97% | |
| ₹232.05 | ₹259.95 | ₹223.10 | ₹232.00 | -0.02% | |
| ₹259.85 | ₹265.00 | ₹230.00 | ₹231.10 | -11.06% | |
| ₹278.00 | ₹278.00 | ₹240.30 | ₹252.10 | -9.32% | |
| ₹240.00 | ₹285.90 | ₹240.00 | ₹277.50 | +15.63% | |
| ₹265.00 | ₹279.80 | ₹239.00 | ₹239.10 | -9.77% | |
| ₹291.95 | ₹299.00 | ₹252.00 | ₹265.00 | -9.23% | |
| ₹222.05 | ₹317.00 | ₹220.25 | ₹291.95 | +31.48% | |
| ₹244.00 | ₹248.00 | ₹199.95 | ₹226.65 | -7.11% | |
| ₹248.15 | ₹274.00 | ₹236.15 | ₹249.45 | +0.52% | |
| ₹197.00 | ₹269.20 | ₹159.00 | ₹248.15 | +25.96% | |
| ₹245.00 | ₹245.00 | ₹182.30 | ₹193.30 | -21.10% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Auro Laboratories Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Auro Laboratories Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of AUROLAB across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Strong Operating Margins (15.95%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (1095.26%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (216.13%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Balanced Promoter Holding (52.18%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
9 factors identified
Below-Average Return on Equity (7.90%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Limited Growth History (-10.74% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Earnings Growth (-12.70% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-12.70% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Elevated Debt Levels (D/E: 1.37)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.
Weak Interest Coverage (2.13x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-0.47 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 0.01%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Auro Laboratories Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Auro Laboratories Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Auro Laboratories LimitedAuro Laboratori...Selected✓ AUROLAB • 530233 | 34.7/100 | ₹251.15₹251 | ₹156.53₹156.53 | 33.41Average 33.4 Average | 7.90%Poor 7.90% Poor | 10.66%Average 10.66% Average | 1.37Average 1.4 Average | -12.70%Poor -12.70% Poor | -10.74%Poor -10.74% Poor | 0.00% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1861.50₹1862 | ₹446629.70₹446629.70 | 36.93Average 36.9 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9452.00₹9452 | ₹250478.00₹250478.00 | 85.76Average 85.8 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4965.50₹4966 | ₹168062.31₹168062.31 | 79.32Average 79.3 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1126.70₹1127 | ₹112444.66₹112444.66 | 25.11Average 25.1 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1375.70₹1376 | ₹111135.92₹111135.92 | 32.96Average 33.0 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1943.50₹1944 | ₹104997.59₹104997.59 | 95.93Average 95.9 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1668.90₹1669 | ₹96028.51₹96028.51 | 26.08Average 26.1 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1140.00₹1140 | ₹95190.00₹95190.00 | 29.46Average 29.5 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2079.30₹2079 | ₹95075.99₹95075.99 | 17.18Average 17.2 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2270.30₹2270 | ₹93763.39₹93763.39 | 45.87Average 45.9 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price446629.70 Cr
- Divi's Laboratories Limited share price250478.00 Cr
- Torrent Pharmaceuticals Limited share price168062.31 Cr
- Zydus Lifesciences Limited share price112444.66 Cr
- Cipla Limited share price111135.92 Cr
Auro Laboratories Limited Quarterly Performance
Latest quarterly metrics for AUROLAB — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
216.13%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
1095.26%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
-10.74%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-12.70%
Compounded annual net profit growth over 5 years
Auro Laboratories Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for AUROLAB — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Auro Laboratories Limited Financial Statements
Annual income statement, balance sheet and cash flow for Auro Laboratories Limited (AUROLAB) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Auro Laboratories Limited
About AUROLAB (Auro Laboratories Limited)
Auro Laboratories Limited is a dynamic and innovative pharmaceutical company dedicated to the development, manufacture, and distribution of high-quality pharmaceutical products. Co...mmitted to improving global health, Auro Laboratories specializes in crafting a diverse portfolio of active pharmaceutical ingredients (APIs) and advanced drug intermediates. Leveraging cutting-edge research and development capabilities, the company focuses on creating novel formulations and improving existing treatment options. With a robust manufacturing infrastructure, Auro Laboratories adheres to the most stringent international quality standards, ensuring the safety and efficacy of every product. Driven by a team of skilled scientists, engineers, and professionals, Auro Laboratories seeks to address unmet medical needs and make a significant impact on healthcare worldwide. Auro Laboratories Limited is recognized for its strategic approach to pharmaceutical manufacturing, focusing on therapeutic areas with significant patient needs. The company's extensive product range encompasses various therapeutic segments, including treatments for allergies, musculoskeletal disorders, metabolic diseases, and infectious diseases. Auro Laboratories develops and manufactures therapies targeting prevalent conditions such as diabetes, fungal infections, and inflammatory ailments, offering affordable and accessible solutions to healthcare providers and patients alike. Furthermore, the company produces essential supplements, including those addressing iron deficiency and iodine deficiencies, ensuring the availability of vital nutrients in vulnerable populations. Dedicated to expanding its reach and impact, Auro Laboratories continuously invests in new product development and market expansion strategies. Auro Laboratories Limited demonstrates unwavering commitment to sustainable and ethical business practices. The company prioritizes environmental responsibility through implementing eco-friendly manufacturing processes and minimizing its environmental footprint. Auro Laboratories upholds the highest ethical standards in all aspects of its operations, fostering a culture of integrity and transparency. By adhering to rigorous regulatory guidelines and quality control measures, Auro Laboratories ensures that every product meets the highest standards of safety, efficacy, and purity. The company emphasizes building strong relationships with its partners, suppliers, and stakeholders based on trust, collaboration, and mutual respect. Auro Laboratories is dedicated to creating a positive impact on society by providing access to affordable, high-quality medicines and promoting responsible business practices.
Company Details
Key Leadership
AUROLAB Share Price: Frequently Asked Questions
What is the current share price of Auro Laboratories Limited?
Auro Laboratories Limited (AUROLAB) trades at ₹251.15 on NSE and BSE. Market cap ₹156.53 (Cr). Educational data only.
What is the P/E ratio of Auro Laboratories Limited?
Auro Laboratories Limited has a P/E of 33.41x vs industry average 34.89x.
What is the Bull Run score for Auro Laboratories Limited?
Auro Laboratories Limited has a Bull Run score of 34.7/100 based on 25+ financial parameters.
Does Auro Laboratories Limited pay dividends?
Auro Laboratories Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Auro Laboratories Limited?
Auro Laboratories Limited has ROE of 7.90%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Auro Laboratories Limited?
Auro Laboratories Limited has debt-to-equity of 1.37.
Is Auro Laboratories Limited a good investment?
Bull Run gives Auro Laboratories Limited a score of 34.7/100. This is not investment advice — consult a SEBI-registered advisor.